TheCitizen - It's all about you
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials
No Result
View All Result
TheCitizen - It's all about you
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials
No Result
View All Result
TheCitizen - It's all about you
No Result
View All Result

Coronavirus: Wealthy nations compete for Remdesivir supplies

The Citizen by The Citizen
July 3 2020
in Global News
A A
0
Coronavirus: Wealthy nations compete for Remdesivir supplies

The world’s wealthiest countries are competing for remdesivir, despite assurances that they would work together to develop drugs that treat COVID-19. Pharmaceuticals giant Gilead Sciences is in an enviable position.

Zolgensma, a gene therapy medicine for treating spinal muscular atrophy in children under the age of two, is now available in Germany. However, a single treatment of the drug, which is produced by Swiss pharmaceuticals company Novartis, comes at the steep price of €1.9 million ($2.1 million).

The manufacturer argues that this is a reasonable price considering that without it, it costs between €2.5 and 4 million to treat the degenerative disease over a lifetime.

Gilead Sciences, which has developed remdesivir, takes a similar line of argument, saying that the drug, which is viewed as a promising tool in the fight against COVID-19, could save costs in the long run.

In an open letter earlier this week, Daniel O’Day, chairman and CEO of Gilead Sciences, wrote: “Taking the example of the United States, earlier hospital discharge would result in hospital savings of approximately $12,000 per patient. Even just considering these immediate savings to the healthcare system alone, we can see the potential value that remdesivir provides.”

“We have decided to price remdesivir well below this value,” he continued. “To ensure broad and equitable access at a time of urgent global need, we have set a price for governments of developed countries of $390 per vial. Based on current treatment patterns, the vast majority of patients are expected to receive a 5-day treatment course using 6 vials of remdesivir, which equates to $2,340 per patient.”

The editor of the German specialist magazine Arznei-Telegramm, Wolfgang Becker-Brüser, is not convinced. He told DW that the costs of treating COVID-19 without remdesivir had been calculated at random.

“There is an attempt to give the impression that the price is fair,” he said. “However, if there wasn’t a pandemic and so much public attention they might have set the price much higher.”

The Association of Research-Based Pharmaceutical Companies (vfa) refused to comment. “The vfa does not comment on the pricing schemes of individual companies,” it said in a statement to DW.

But in the past, the vfa has called on the pharmaceuticals sector to show responsibility with regard to consumers and demanded that affordable medicine and vaccines be made available.

An analysis by British researchers cited in the Germany weekly Der Spiegel came to the conclusion that it probably cost about €8 to produce one dose of remdesivir.

However, it is normal for the sale price to be much higher than the production price, considering companies invest huge sums into development.

Gilead Sciences claims that it invested about $1 billion into remdesivir. This is actually at the lower end of the vfa’s scale for developing a new drug. The association told DW that companies tended to invest $1 to 1.6 billion in a new product.

For Wolfgang Becker-Brüser, this is “fantasy.”

“If the development costs are calculated to be so high then it is easy to demand higher prices,” he told DW.

For Alexander Nuyken, a pharmaceuticals expert at the consulting firm EY, there is a reason that development costs are so high: they encompass the risk of failure. “It has to be possible to add a premium for the risks incurred from the development of a drug to its approval,” he said.

Becker-Brüser said that in general drugs were becoming more expensive. “The number of prescriptions for new patented drugs is the same but their price is going up,” he said. This was already the case before the COVID-19 pandemic, as indicated by a report by the German health insurance company AOK from last year, according to which insurance companies are paying an increasingly high proportion of their medicine budget on particularly expensive drugs. Drugs as pricey as Zolgensma are only the tip of the iceberg.

With regard to remdesivir, however, there had been some expectation that the cost per course of treatment would actually be higher. The Institute for Clinical and Economic Review, a US-based nonprofit organization that analyzes drug prices, had suggested that a reasonable price would be $2,800, while others had recommended $4,000.

But considering that remdesivir is practically a waste product, which Gilead Sciences originally developed to treat Ebola, without major success, Becker-Brüser presumes that the company opted for a compromise in view of the public pressure.

It could turn out to be a win-win situation for the company. Its share price rose when the price of remdesivir was announced earlier this week and orders have gone through the roof.

According to media reports, the US has already secured the entire stock of projected production for July and 90% for August.

Germany, too, has apparently secured supplies. Health Minister Jens Spahn has been applying pressure. He said that he expected “Germany and Europe to have access to supplies to such a drug.” The British government has also said that it has enough reserves.

So far, remdesivir has not been fully approved in any country and there has not been enough research into how effective it really is against the novel coronavirus. But apart from Dexamethason, it is the drug that seems to have the most potential for treating patients with SARS-CoV-2 and limiting the disease’s course.

Alexander Nuyken said that it was not surprising that the world’s wealthy nations were all eager to get hold of supplies. “That’s why it is particularly important that we find common solutions in international alliances.”

There are already several international forums in which this is being attempted and a European vaccine alliance has been formed with the WHO.

However, the problem, as with the global fight against the climate emergency, is that if the US does not play by the same rules, the attempts of other states will be curbed.

Those who benefit, said Becker-Brüser, are the pharmaceuticals giants, “which are in a position to aim higher.”

It will soon become clear how high Gilead Sciences is prepared to go. Right now, the European Union is negotiating with the US company and trying to ensure that all 27 states have supplies in the coming months. – DW.

 

Previous Post

UN suspends two officials over viral car-sex video

Next Post

MultiChoice decision to drop EPL, Champions League rights deals blow to fresh industry players

Related Posts

US intelligence agency scrambles as classified communications network goes down
Global News

US intelligence agency scrambles as classified communications network goes down

November 18 2026
South Africa cautions Fani-Kayode over social media remarks
Global News

South Africa cautions Fani-Kayode over social media remarks

November 18 2026
Canada flags Nigeria, 16 African countries as high-risk in new travel advisory
Global News

Canada to fast-track permanent residence for 200,000 foreigners in 2027

November 12 2026
Court overturns gay sex ban in Trinidad & Tobago
Global News

Court overturns gay sex ban in Trinidad & Tobago

November 11 2026
US warns citizens against travel to 23 countries
Global News

US warns citizens against travel to 23 countries

November 10 2026
Russia agrees to ban recruitment of Ghanaian nationals for Ukraine war
Global News

Russia agrees to ban recruitment of Ghanaian nationals for Ukraine war

November 2 2026
Next Post
MultiChoice decision to drop EPL, Champions League rights deals blow to fresh industry players

MultiChoice decision to drop EPL, Champions League rights deals blow to fresh industry players

Premier League: Man City trash Liverpool 4-0

Premier League: Man City trash Liverpool 4-0

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FROM THE GRASSROOTS

Fasoranti: Family announces Dec 17 for funeral

Fasoranti: Family announces Dec 17 for funeral

by The Editor
October 23 2026
0

...

Ooni, Omisore mourn Afenifere leader Fasoranti

Ooni, Omisore mourn Afenifere leader Fasoranti

by The Editor
October 21 2026
0

...

Minister defends King’s College concession, cites infrastructure decay

Minister defends King’s College concession, cites infrastructure decay

by The Editor
September 16 2026
0

...

Lagos demolishes shanties after four die in community clash

Lagos demolishes shanties after four die in community clash

by The Editor
August 30 2026
0

...

APPOINTMENTS

Benue Justice Commissioner resigns with immediate effect

Benue Justice Commissioner resigns with immediate effect

by The Editor
November 18 2026
0

...

Makinde swears in four Oyo permanent secretaries

Makinde swears in four Oyo permanent secretaries

by The Editor
November 10 2026
0

...

Enugu APC releases updated campaign council list

by The Editor
October 31 2026
0

...

Gov. Okpebholo elevates ex-BBNaija housemate to adviser

Gov. Okpebholo elevates ex-BBNaija housemate to adviser

by The Editor
October 22 2026
0

...

ODDITIES

Kano woman allegedly hires men to kill co-wife’s children over inheritance

Kano woman allegedly hires men to kill co-wife’s children over inheritance

by The Editor
November 18 2026
0

Man stabs neighbor to death over roasted meat

Man stabs neighbor to death over roasted meat

by The Editor
November 5 2026
0

US pastor marries second wife, says monogamy unbiblical

US pastor marries second wife, says monogamy unbiblical

by The Editor
October 26 2026
0

GLOBAL NEWS

US intelligence agency scrambles as classified communications network goes down

US intelligence agency scrambles as classified communications network goes down

by The Editor
November 18 2026
0

...

South Africa cautions Fani-Kayode over social media remarks

South Africa cautions Fani-Kayode over social media remarks

by The Editor
November 18 2026
0

...

Canada flags Nigeria, 16 African countries as high-risk in new travel advisory

Canada to fast-track permanent residence for 200,000 foreigners in 2027

by The Editor
November 12 2026
0

...

Court overturns gay sex ban in Trinidad & Tobago

Court overturns gay sex ban in Trinidad & Tobago

by The Editor
November 11 2026
0

...

US warns citizens against travel to 23 countries

US warns citizens against travel to 23 countries

by The Editor
November 10 2026
0

...

State of the States

Katsina mob kills Customs officer for shooting passenger

Hisbah bans girls’ night hawking in Katsina

by The Editor
November 12 2026
0

...

Kano closes schools for Eid-el-Kabir

Kano governor unveils N50,000 grants for 5,200 women

by The Editor
November 10 2026
0

...

Delta SUBEB denies N13.4bn unspent funds claim

Delta SUBEB denies N13.4bn unspent funds claim

by The Editor
October 31 2026
0

...

Ogun State mulls relocation of communities over gas leak

Ogun State mulls relocation of communities over gas leak

by The Editor
October 23 2026
0

...

Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
ASUU, TCN, 30 others join NLC nationwide strike

Labour needs unity, not needless bickering – Punch

November 18 2026
Super Eagles face AFCON qualifiers hurdle after Tanzania draw

Super Eagles face AFCON qualifiers hurdle after Tanzania draw

November 18 2026
Atiku names Kashim-Ibrahim campaign chair, El-Rufai deputy

Atiku’s candidacy: ADC files 17-ground appeal

November 18 2026
FG orders recovery of excess payments to university workers

FG orders recovery of excess payments to university workers

November 18 2026

EDITORIAL REVIEW

ASUU, TCN, 30 others join NLC nationwide strike

Labour needs unity, not needless bickering – Punch

by The Editor
November 18 2026
0

Flamingos: All hail world champions! – Punch

Flamingos: All hail world champions! – Punch

by The Editor
November 12 2026
0

FG outlines criteria for N50k cash grant beneficiaries

Tinubu’s N50,000 relief for the vulnerable – Punch

by The Editor
November 11 2026
0

There are drug addicts, vagabonds among traditional rulers, says Obasanjo

13% derivation: Fiscal federalism to the rescue – Punch

by The Editor
November 10 2026
0

Nigeria’s damning food affordability crisis – Punch

Nigeria’s damning food affordability crisis – Punch

by The Editor
November 2 2026
0

Opinion

NAFDAC mops up Europharm products nationwide

What is a Nigerian’s life worth?

by The Editor
November 2 2026
0

...

Blackouts: Broken promises, powering failure – Punch

The revenge of Band A

by The Editor
October 27 2026
0

...

2027: Wike, APC governors clash over Rainbow Coalition

Why are governors getting worse?

by The Editor
October 13 2026
0

...

As we celebrate the girl-child, let us not forget the boy-child

As we celebrate the girl-child, let us not forget the boy-child

by The Editor
October 12 2026
0

...

Plugin Install : Popular Post Widget need JNews - View Counter to be installed
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials

© 2026 TheCitizen Ng. All Rights Reserved.

No Result
View All Result
  • Home
  • Headlines
  • Latest News
  • Governance
  • Business
  • Financial Crimes
  • Opinion
  • Editorials

© 2026 TheCitizen Ng. All Rights Reserved.